Show simple item record

dc.contributor.authorBurg, Ashley R.*
dc.contributor.authorQuigley, Laura*
dc.contributor.authorJones, Adam V.*
dc.contributor.authorO'Connor, Geraldine M.*
dc.contributor.authorBoelte, Kimberly*
dc.contributor.authorMcVicar, Daniel W.*
dc.contributor.authorOrr, Selinda J.*
dc.date.accessioned2016-07-19T13:28:11Z
dc.date.available2016-07-19T13:28:11Z
dc.date.issued2016-06-21
dc.identifier.citationBurg, A. R., Quigley, L., Jones, A. V., O'Connor, G. M., Boelte, K., McVicar, D. W., & Orr, S. J. (2016). Orally administered beta-glucan attenuates the Th2 response in a model of airway hypersensitivity. Springerplus, 5(1), 815. doi:10.1186/s40064-016-2501-1
dc.identifier.doi10.1186/s40064-016-2501-1
dc.identifier.urihttp://hdl.handle.net/10034/617246
dc.descriptionThe final publication is available at Springer via http://dx.doi.org/10.1186/s40064-016-2501-1
dc.description.abstractbeta-Glucan is a polysaccharide that can be extracted from fungal cell walls. Wellmune WGP((R)), a preparation of beta-1,3/1,6-glucans, is a dietary supplement that has immunomodulating properties. Here we investigated the effect WGP had on a mouse model of asthma. OVA-induced asthma in mice is characterized by infiltration of eosinophils into the lung, production of Th2 cytokines and IgE. Daily oral administration of WGP (400 microg) significantly reduced the influx of eosinophils into the lungs of OVA-challenged mice compared to control mice. In addition, WGP inhibited pulmonary production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment. These data indicate that WGP could potentially be useful as an oral supplement for some asthma patients, however, it would need to be combined with therapies that target other aspects of the disease such as IgE levels. As such, further studies that examine the potential of WGP in combination with other therapies should be explored.
dc.language.isoenen
dc.publisherSpringerOpen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916077/en
dc.relation.urlhttp://link.springer.com/article/10.1186/s40064-016-2501-1/fulltext.htmlen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectAsthmaen
dc.subjectImmunomodulationen
dc.titleOrally administered beta-glucan attenuates the Th2 response in a model of airway hypersensitivityen
dc.typeArticle
dc.identifier.eissn2193-1801
dc.contributor.departmentNational Cancer Institute-Frederick; University of Alabama at Birmingham; University Dental Hospital, Cardiff and Vale University Health Board; University of Chester; Cardiff University School of Medicine
dc.identifier.journalSpringerPlusen
dc.date.accepted2016-05-31
or.grant.openaccessYesen
rioxxterms.funderNIH Office of Dietary Supplementsen
rioxxterms.identifier.projectExternally Funded - not through Chester Universityen
rioxxterms.versionAMen
rioxxterms.licenseref.startdate2016-06-21
html.description.abstractbeta-Glucan is a polysaccharide that can be extracted from fungal cell walls. Wellmune WGP((R)), a preparation of beta-1,3/1,6-glucans, is a dietary supplement that has immunomodulating properties. Here we investigated the effect WGP had on a mouse model of asthma. OVA-induced asthma in mice is characterized by infiltration of eosinophils into the lung, production of Th2 cytokines and IgE. Daily oral administration of WGP (400 microg) significantly reduced the influx of eosinophils into the lungs of OVA-challenged mice compared to control mice. In addition, WGP inhibited pulmonary production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment. These data indicate that WGP could potentially be useful as an oral supplement for some asthma patients, however, it would need to be combined with therapies that target other aspects of the disease such as IgE levels. As such, further studies that examine the potential of WGP in combination with other therapies should be explored.


Files in this item

Thumbnail
Name:
Burg 2016_Accepted.pdf
Size:
654.7Kb
Format:
PDF
Request:
Main Article

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/